AI Article Synopsis
- - The case study discusses a patient with pancreatic carcinoma characterized by NTRK fusion positivity, which means the cancer cells have a specific genetic alteration.
- - The patient also suffers from congenital long QT syndrome, a heart condition that can lead to serious irregular heartbeats, complicating treatment options.
- - Repotrectinib, a targeted therapy drug designed to inhibit NTRK fusion proteins, was administered to the patient, aiming to address both the cancer and the patient's unique health challenges.
Article Abstract
Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital long QT syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830087 | PMC |
| http://dx.doi.org/10.1200/PO.23.00265 | DOI Listing |
Publication Analysis
Top Keywords
repotrectinib patient
8
fusion-positive pancreatic
8
pancreatic carcinoma
8
carcinoma congenital
8
congenital long
8
long syndrome
8
patient fusion-positive
4
syndrome repotrectinib
4
patient ntrk
4
ntrk fusion-positive
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!